Work

Supplementary Figure 1a from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib

Year: 2023

Type: supplementary-materials

Abstract: Patients #1, #3, #4, #6, #7, and #8 experienced progressive disease while on vandetanib therapy. Calcitonin and CEA are shown as percent change from baseline at the start of vandetanib therapy (left y-axis). Tumor size is the sum of longest diameter of lesions per RECISTv1.0 (right y-axis).

DOI: 10.1158/1078-0432.22464200.v1

Authors: Ira L. Kraft, Srivandana Akshintala, Yuelin Zhu, Haiyan Lei, Claudia Derse-Anthony, Eva Dombi, Seth M. Steinberg, Maya Lodish, Steven G. Waguespack, Oxana Kapustina, Elizabeth Fox, Frank M. Balis, Maria J. Merino, Paul S. Meltzer, John W. Glod, Jack F. Shern, Brigitte C. Widemann

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361923213

Cites:

Cited by:

Related to: 10